Wall Street analysts predict that DexCom, Inc. (NASDAQ:DXCM) will post earnings per share of $0.19 for the current fiscal quarter, according to Zacks Investment Research. Ten analysts have provided estimates for DexCom’s earnings, with estimates ranging from $0.01 to $0.31. DexCom reported earnings of $0.17 per share in the same quarter last year, which would suggest a positive year over year growth rate of 11.8%. The company is expected to report its next quarterly earnings report on Tuesday, November 5th.
According to Zacks, analysts expect that DexCom will report full-year earnings of $0.94 per share for the current year, with EPS estimates ranging from $0.73 to $1.10. For the next fiscal year, analysts expect that the firm will post earnings of $1.35 per share, with EPS estimates ranging from $1.05 to $1.77. Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that that provide coverage for DexCom.
DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Wednesday, July 31st. The medical device company reported $0.08 EPS for the quarter, beating analysts’ consensus estimates of $0.01 by $0.07. The company had revenue of $336.40 million during the quarter, compared to analysts’ expectations of $304.40 million. DexCom had a positive return on equity of 10.41% and a negative net margin of 13.96%. DexCom’s revenue was up 38.7% on a year-over-year basis. During the same period in the prior year, the business posted ($0.10) EPS.
Shares of DXCM traded up $4.93 on Friday, hitting $163.46. The company’s stock had a trading volume of 35,097 shares, compared to its average volume of 897,191. The company has a quick ratio of 5.64, a current ratio of 6.05 and a debt-to-equity ratio of 1.56. The firm’s fifty day moving average price is $150.54 and its 200-day moving average price is $136.32. DexCom has a fifty-two week low of $105.05 and a fifty-two week high of $161.30. The firm has a market capitalization of $14.46 billion, a price-to-earnings ratio of 545.50 and a beta of 0.80.
In other DexCom news, EVP Richard Doubleday sold 2,016 shares of the company’s stock in a transaction that occurred on Tuesday, July 23rd. The stock was sold at an average price of $153.56, for a total transaction of $309,576.96. Following the completion of the transaction, the executive vice president now owns 72,570 shares of the company’s stock, valued at approximately $11,143,849.20. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Patrick Michael Murphy sold 400 shares of the company’s stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $127.03, for a total value of $50,812.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 55,665 shares of company stock valued at $7,344,275. Insiders own 1.80% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in the business. Bamco Inc. NY raised its stake in DexCom by 20.9% in the 2nd quarter. Bamco Inc. NY now owns 500,244 shares of the medical device company’s stock valued at $74,957,000 after acquiring an additional 86,347 shares during the period. Voloridge Investment Management LLC raised its stake in DexCom by 237.0% in the 2nd quarter. Voloridge Investment Management LLC now owns 63,562 shares of the medical device company’s stock valued at $9,524,000 after acquiring an additional 44,701 shares during the period. Voleon Capital Management LP bought a new stake in DexCom in the 2nd quarter valued at $1,199,000. Waddell & Reed Financial Inc. raised its stake in DexCom by 1.8% in the 2nd quarter. Waddell & Reed Financial Inc. now owns 1,056,250 shares of the medical device company’s stock valued at $158,269,000 after acquiring an additional 18,247 shares during the period. Finally, Nuveen Asset Management LLC increased its position in DexCom by 1,781.3% during the 2nd quarter. Nuveen Asset Management LLC now owns 1,107,735 shares of the medical device company’s stock worth $165,983,000 after buying an additional 1,048,855 shares during the period. 96.13% of the stock is owned by hedge funds and other institutional investors.
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
Recommended Story: Operating Income
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.